AFFITOPE PD01A / ACI-7104.056 vs UB-312
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
AFFITOPE PD01A / ACI-7104.056
Developed by AC Immune and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT06015841 (registry estimate)
No aligned efficacy figure on record for this race.
UB-312
Developed by Vaxxinity
NCT04075318 · Phase 1 · completed
A randomized, quadruple-blind, placebo-controlled phase 1 study of the UB-312 vaccine in 70 participants. The design is sound but small, and its primary measures were safety and immunogenicity: anti-alpha-synuclein antibody responses were reported in blood while cerebrospinal-fluid responses were only partial, with no statistical analyses posted, so the primary outcomes read as mixed.
Reported efficacy
Frequency of Adverse Events (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in Blood (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in CSF (44 weeks): Frequency of Adverse Events (44 weeks): Part A: UB-312 40 mcg 22 TEAEs | Part A: UB-312 100 mcg 31 TEAEs | Part A: UB-312 40/300 mcg 25 TEAEs | Part A: UB-312 300 mcg 31 TEAEs | Part A: UB-312 40/1000 mcg 24 TEAEs | Part A: UB-312 1000 mcg 17 TEAEs | Part A: UB-312 2000 mcg 18 TEAEs | Part A: Placebo 25 TEAEs | Part B: UB-312 300/100 mcg 59 TEAEs | Part B: UB-312 300 mcg 42 TEAEs | Part B: Placebo 20 TEAEs (mixed)
Result source: NCT04075318
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AFFITOPE PD01A / ACI-7104.056 | UB-312 |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- AFFITOPE PD01A / ACI-7104.056
- —Not reported
- UB-312
- —Not reported
ON time without troublesome dyskinesia, change
- AFFITOPE PD01A / ACI-7104.056
- —Not reported
- UB-312
- —Not reported
UPDRS Part III, change
- AFFITOPE PD01A / ACI-7104.056
- —Not reported
- UB-312
- —Not reported
MDS-UPDRS Part II, change
- AFFITOPE PD01A / ACI-7104.056
- —Not reported
- UB-312
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AFFITOPE PD01A / ACI-7104.056: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. AFFITOPE PD01A / ACI-7104.056: 0 of 4 rows · UB-312: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | UB-312 |
|---|---|
| Dropout rate | 100%2000 mcga NCT04075318 · Phase 1 · monotherapy show 8 more results100%1000 mcg NCT04075318 · Phase 1 · monotherapy 100%40/1000 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 16.7%40/300 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 14.3%300/100 mcg NCT04075318 · Phase 1 · monotherapy 0%100 mcg NCT04075318 · Phase 1 · monotherapy 0%40 mcg NCT04075318 · Phase 1 · monotherapy |
| Discontinued due to AEs | —2000 mcga NCT04075318 · Phase 1 · monotherapy show 8 more results—1000 mcg NCT04075318 · Phase 1 · monotherapy —40/1000 mcg NCT04075318 · Phase 1 · monotherapy —300 mcg NCT04075318 · Phase 1 · monotherapy —40/300 mcg NCT04075318 · Phase 1 · monotherapy —300 mcg NCT04075318 · Phase 1 · monotherapy —300/100 mcg NCT04075318 · Phase 1 · monotherapy —100 mcg NCT04075318 · Phase 1 · monotherapy —40 mcg NCT04075318 · Phase 1 · monotherapy |
| Serious AEs | 0%2000 mcga NCT04075318 · Phase 1 · monotherapy show 8 more results0%1000 mcg NCT04075318 · Phase 1 · monotherapy 0%40/1000 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 0%40/300 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 42.9%300/100 mcg NCT04075318 · Phase 1 · monotherapy 0%100 mcg NCT04075318 · Phase 1 · monotherapy 0%40 mcg NCT04075318 · Phase 1 · monotherapy |
| Most frequent reported AEs | 2000 mcga general disorders and administration site conditions 83.3% (placebo 62.5%) nervous system disorders 66.7% (placebo 62.5%) infections and infestations 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy show 8 more results1000 mcg general disorders and administration site conditions 100% (placebo 62.5%) infections and infestations 33.3% (placebo 62.5%) nervous system disorders 33.3% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 40/1000 mcg general disorders and administration site conditions 66.7% (placebo 62.5%) infections and infestations 50% (placebo 62.5%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 300 mcg general disorders and administration site conditions 100% (placebo 62.5%) muscoloskeletal and connective tissue disorders 66.7% (placebo 25%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 40/300 mcg general disorders and administration site conditions 66.7% (placebo 62.5%) infections and infestations 50% (placebo 62.5%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 300 mcg nervous system disorders 100% (placebo 62.5%) infections and infestations 71.4% (placebo 62.5%) vascular disorders 42.9% (placebo 0%) NCT04075318 · Phase 1 · monotherapy 300/100 mcg injury, poisoning and procedural complications 85.7% (placebo 0%) nervous system disorders 85.7% (placebo 62.5%) general disorders and administration site conditions 57.1% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 100 mcg general disorders and administration site conditions 66.7% (placebo 62.5%) infections and infestations 66.7% (placebo 62.5%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 40 mcg general disorders and administration site conditions 83.3% (placebo 62.5%) nervous system disorders 66.7% (placebo 62.5%) muscoloskeletal and connective tissue disorders 33.3% (placebo 25%) NCT04075318 · Phase 1 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AFFITOPE PD01A / ACI-7104.056's landscape · UB-312's landscape